Longeveron (LGVN) Price & Analysis

Compare

582 Followers

LGVN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.63 - $2.48

Previous CloseN/A

Volume215.49K

Average Volume (3M)1.44M

Market Cap

$17.01M

Enterprise Value$10.32M

Total Cash (Recent Filing)$10.33M

Total Debt (Recent Filing)$639.00K

Price to Earnings (P/E)―

Beta1.44

Next Earnings

Nov 07, 2025

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding19,312,218

10 Day Avg. Volume2,631,813

30 Day Avg. Volume1,439,762

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.61

Enterprise Value/Revenue4.98

Enterprise Value/Gross Profit6.32

Enterprise Value/Ebitda-0.55

Forecast

1Y Price Target

$3.50

Price Target Upside326.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial SupportGrant funding from the National Institute of Health offsets the expenses of the study, providing financial support for the research.

Partnership OpportunitiesLongeveron has gained FDA alignment on an adaptive single P2/3 pivotal trial design for Alzheimer's disease, which should make the program more attractive for partnering with a larger company.

Regulatory SupportThe FDA's ongoing commitment to streamlining approvals for rare diseases, particularly rare pediatric diseases, is expected to support the company's filing on a positive note.

Bears Say

Capital RequirementsLongeveron reported a net loss, and it is expected that the company will require additional capital.

Financial PerformanceThe company's recent equity financing has led to dilution, which has contributed to a lowered 12-month price target from $6.00 to $4.00.

Regulatory RisksRisks include the potential failure of Lomecel-B in the ELPIS-II trial of HLHS patients and inability to obtain regulatory approval.

Longeveron News

Longeveron price target lowered to $3 from $10 at Roth Capital

Roth Capital lowered the firm’s price target on Longeveron (LGVN) to $3 from $10 and keeps a Buy...

14d ago

LGVN

Longeveron announces $17.5M Class A common stock offering

Longeveron (LGVN) announced the pricing of a public offering of 5.88M of the company’s Class A common stock,...

21d ago

LGVN

Longeveron files to sell 3.85M shares of Class A common stock

16:05 EDT Longeveron (LGVN) files to sell 3.85M shares of Class A common stock Published first on TheFly...

24d ago

LGVN

Longeveron: Buy Rating Backed by Promising Clinical Developments and Strategic Financial Outlook

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on LGVN stock, giving a Buy rating yesterday....

14d ago

LGVN

Longeveron Inc. Faces Regulatory and Manufacturing Challenges Threatening Financial Stability

Longeveron Inc. (LGVN) has disclosed a new risk, in the Manufacturing category. Longeveron Inc. faces significant business risks...

14d ago

LGVN

Longeveron Inc. Reports Q2 2025 Financial Results

Longeveron Inc. ( ($LGVN) ) has released its Q2 earnings. Here is a breakdown of the information Longeveron...

15d ago

LGVN

Longeveron Closes $5 Million Public Stock Offering

Longeveron ( ($LGVN) ) has issued an announcement. On August 8, 2025, Longeveron announced the pricing of a...

17d ago

LGVN

LGVN Earnings this Week: How Will it Perform?

Longeveron Inc. (LGVN) is scheduled to report 2nd quarter earnings on 08/13/2025, after the market closes. Regarding Q2...

18d ago

LGVN

Longeveron licenses patent for stem cell technology from University of Miami

Longeveron (LGVN) has licensed an issued US patent for a stem cell technology from the University of Miami....

1M ago

LGVN

Longeveron Gains FDA Approval for Laromestrocel Trial

An announcement from Longeveron ( ($LGVN) ) is now available. On July 8, 2025, Longeveron Inc. announced that...

2M ago

LGVN

Longeveron Receives Buy Rating: Promising Pipeline and Strategic Expansion into Pediatric Cardiomyopathy

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron, with a...

2M ago

LGVN

Longeveron announces FDA approval of IND application for laromestrocel study

Longeveron (LGVN) announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for...

2M ago

LGVN

Longeveron appoints Powell as Chief Business Officer

Longeveron (LGVN) announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In...

2M ago

LGVN

Positive Buy Rating for Longeveron Driven by Phase 2b Study Milestone and Favorable Market Conditions

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron (LGVN –...

2M ago

LGVN

LGVN FAQ

What was Longeveron’s price range in the past 12 months?

Longeveron lowest stock price was $0.63 and its highest was $2.48 in the past 12 months.

What is Longeveron’s market cap?

Longeveron’s market cap is $17.01M.

When is Longeveron’s upcoming earnings report date?

Longeveron’s upcoming earnings report date is Nov 07, 2025 which is in 70 days.

How were Longeveron’s earnings last quarter?

Longeveron released its earnings results on Aug 13, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.02.

Is Longeveron overvalued?

According to Wall Street analysts Longeveron’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Longeveron pay dividends?

Longeveron does not currently pay dividends.

What is Longeveron’s EPS estimate?

Longeveron’s EPS estimate is -0.26.

How many shares outstanding does Longeveron have?

Longeveron has 19,312,218 shares outstanding.

What happened to Longeveron’s price movement after its last earnings report?

Longeveron reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went down -11.628%.

Which hedge fund is a major shareholder of Longeveron?

Currently, no hedge funds are holding shares in LGVN

Company Description

Longeveron

Longeveron Inc. is a biotechnology company focused on developing cellular therapies for aging-related and life-threatening conditions. The company is engaged in the research and development of regenerative medicine, specializing in the use of medicinal signaling cells (MSCs) derived from donor bone marrow. Longeveron aims to harness the potential of these cells to address medical conditions associated with aging, such as frailty, and other severe diseases, thereby improving patient outcomes and enhancing quality of life.

Longeveron (LGVN) Earnings & Revenues

Historic Earnings Reports

LGVN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call highlighted significant progress in clinical trials and pipeline expansion, alongside strategic moves in manufacturing readiness and financial planning. However, these were tempered by declines in revenue and increased expenses, alongside some regulatory and financial uncertainties.View all LGVN earnings summaries

LGVN Stock 12 Month Forecast

Average Price Target

$3.50

▲(326.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","1.25":"$1.25","2.5":"$2.5","3.75":"$3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.64,1.8215384615384616,2.003076923076923,2.184615384615385,2.3661538461538463,2.5476923076923077,2.729230769230769,2.9107692307692306,3.0923076923076924,3.2738461538461543,3.4553846153846157,3.636923076923077,3.8184615384615386,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.64,1.783076923076923,1.926153846153846,2.069230769230769,2.212307692307692,2.355384615384615,2.4984615384615383,2.6415384615384614,2.7846153846153845,2.9276923076923076,3.0707692307692307,3.213846153846154,3.356923076923077,{"y":3.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.64,1.7446153846153845,1.8492307692307692,1.9538461538461538,2.0584615384615383,2.163076923076923,2.2676923076923075,2.3723076923076922,2.476923076923077,2.581538461538462,2.686153846153846,2.7907692307692304,2.8953846153846152,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.85,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >